Krista L Lanctôt Selected Research

Cholinesterase Inhibitors (Anticholinesterases)

1/2020	Canadian Consensus Conference on Diagnosis and Treatment of Dementia (CCCDTD)5: Guidelines for management of vascular cognitive impairment.
12/2016	Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
2/2016	A Randomized Placebo-Controlled Discontinuation Study of Cholinesterase Inhibitors in Institutionalized Patients With Moderate to Severe Alzheimer Disease.
11/2015	Cholinesterase inhibitor discontinuation in patients with Alzheimer's disease: a meta-analysis of randomized controlled trials.
7/2013	Pharmacological recommendations for the symptomatic treatment of dementia: the Canadian Consensus Conference on the Diagnosis and Treatment of Dementia 2012.
9/2011	Revisiting the cholinergic hypothesis of behavioral and psychological symptoms in dementia of the Alzheimer's type.
5/2011	Discontinuing cholinesterase inhibitors: results of a survey of Canadian dementia experts.
11/2010	The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease.
12/2008	The effect of cholinesterase inhibitors on decline in multiple functional domains in Alzheimer's disease: a two-year observational study in the Sunnybrook dementia cohort.
7/2007	Commentary on "Health economics and the value of therapy in Alzheimer's disease." Cholinesterase inhibitors in Alzheimer's disease--evidence-based or evidence-biased?

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Krista L Lanctôt Research Topics

Disease

63	Alzheimer Disease (Alzheimer's Disease) 01/2022 - 06/2002
32	Dementia (Dementias) 11/2022 - 01/2003
27	Cognitive Dysfunction 01/2022 - 10/2002
26	Coronary Artery Disease (Coronary Atherosclerosis) 01/2021 - 03/2008
11	Major Depressive Disorder (Major Depressive Disorders) 01/2021 - 09/2011
10	Stroke (Strokes) 12/2020 - 06/2004
7	Inflammation (Inflammations) 01/2022 - 10/2011
6	Psychotic Disorders (Schizoaffective Disorder) 01/2022 - 01/2004
6	Respiratory Syncytial Virus Infections 08/2019 - 06/2002
4	Pain (Aches) 01/2022 - 01/2018
4	Type 2 Diabetes Mellitus (MODY) 01/2021 - 01/2019
3	Weight Loss (Weight Reduction) 09/2019 - 08/2013
3	Respiratory Tract Infections (Respiratory Tract Infection) 03/2017 - 06/2002
3	Traumatic Brain Injuries (Traumatic Brain Injury) 09/2010 - 06/2008
2	Mixed Dementias 01/2022 - 01/2005
2	Glucose Intolerance 12/2020 - 01/2006
2	Weight Gain 01/2020 - 01/2006
2	Congenital Heart Defects (Congenital Heart Defect) 08/2019 - 05/2017
2	Aortic Valve Stenosis (Aortic Stenosis) 01/2018 - 01/2015
2	Neoplasms (Cancer) 01/2011 - 07/2002
2	Sleep Initiation and Maintenance Disorders (Insomnia) 06/2008 - 11/2005
1	Transient Ischemic Attack 12/2020
1	Insulin Resistance 12/2020
1	Diabetes Mellitus 12/2020

Drug/Important Bio-Agent (IBA)

15	Biomarkers (Surrogate Marker)IBA 01/2022 - 09/2010
15	Antidepressive Agents (Antidepressants)IBA 01/2021 - 05/2005
14	Cholinesterase Inhibitors (Anticholinesterases)IBA 01/2020 - 01/2003
12	Palivizumab FDA Link 01/2019 - 06/2002
8	Methylphenidate (Ritalin)FDA LinkGeneric 11/2021 - 06/2008
6	Pharmaceutical PreparationsIBA 10/2018 - 01/2003
5	Memantine (Namenda)FDA Link 01/2022 - 11/2010
5	CannabinoidsIBA 01/2020 - 08/2015
5	LipidsIBA 01/2017 - 09/2013
4	nabilone (Cesamet)FDA Link 01/2020 - 01/2019
4	SphingolipidsIBA 01/2020 - 01/2017
4	Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA 02/2017 - 07/2012
4	Antipsychotic Agents (Antipsychotics)IBA 07/2013 - 06/2004
3	Galantamine (Galanthamine)FDA LinkGeneric 01/2022 - 09/2004
3	Brain-Derived Neurotrophic Factor (BDNF)IBA 01/2022 - 10/2018
3	Apolipoproteins E (ApoE)IBA 11/2021 - 03/2020
3	Hydrocortisone (Cortisol)FDA LinkGeneric 01/2020 - 09/2010
3	CytokinesIBA 01/2020 - 09/2010
3	4-hydroxy-2-nonenal (4-hydroxynonenal)IBA 12/2018 - 01/2017
3	C-Reactive ProteinIBA 05/2018 - 09/2010
3	Citalopram FDA LinkGeneric 09/2012 - 01/2010
3	Donepezil (Aricept)FDA LinkGeneric 11/2010 - 09/2004
3	Risperidone (Risperdal Consta)FDA LinkGeneric 10/2007 - 06/2004
3	Olanzapine (Zyprexa)FDA Link 10/2007 - 06/2004
2	Biological ProductsIBA 11/2022 - 01/2021
2	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 12/2020
2	Amyloid (Amyloid Fibrils)IBA 01/2021 - 10/2011
2	Oxygen (Dioxygen)IBA 01/2019 - 03/2017
2	Phospholipids (Phosphatides)FDA LinkGeneric 01/2018 - 03/2016
2	Cholinergic Agents (Cholinergics)IBA 01/2018 - 09/2011
2	CeramidesIBA 01/2018 - 12/2013
2	Interleukin-6 (Interleukin 6)IBA 10/2017 - 09/2010
2	Unsaturated Fatty Acids (Polyunsaturated Fatty Acids)IBA 02/2017 - 10/2016
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2016 - 07/2002
2	Platelet Activating FactorIBA 01/2015 - 09/2013
2	KynurenineIBA 02/2011 - 11/2009
2	Indoleamine-Pyrrole 2,3,-Dioxygenase (Indoleamine 2,3 Dioxygenase)IBA 02/2011 - 11/2009
2	Tryptophan (L-Tryptophan)FDA Link 02/2011 - 11/2009
2	Rivastigmine (Exelon)FDA LinkGeneric 11/2010 - 09/2004
2	Neurotransmitter Agents (Neurotransmitter)IBA 05/2009 - 07/2004
2	Dextroamphetamine (Dexedrine)FDA LinkGeneric 07/2008 - 06/2008
2	Serotonin (5 Hydroxytryptamine)IBA 12/2007 - 10/2002
1	Glutathione (Reduced Glutathione)IBA 01/2022
1	Medical MarijuanaIBA 01/2022
1	antibiotic K 4 (K 4)IBA 01/2022
1	Opioid Analgesics (Opioids)IBA 01/2022
1	Proton Pump InhibitorsIBA 01/2022
1	Nimodipine (Modus)FDA LinkGeneric 01/2022
1	BenzodiazepinesIBA 01/2022
1	salicylhydroxamic acid (SHAM)IBA 12/2021
1	Angiotensin Receptor AntagonistsIBA 11/2021
1	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 11/2021
1	zafirlukast (Accolate)FDA LinkGeneric 01/2021
1	Epoxide HydrolasesIBA 01/2021
1	Glutathione PeroxidaseIBA 01/2021
1	LeukotrienesIBA 01/2021
1	OxylipinsIBA 01/2021
1	montelukast (Singulair)FDA Link 01/2021
1	Leukotriene Antagonists (Leukotriene Receptor Antagonists)IBA 01/2021
1	OsteocalcinIBA 12/2020
1	Hypoglycemic Agents (Hypoglycemics)IBA 12/2020
1	Dipeptidyl-Peptidase IV InhibitorsIBA 12/2020
1	Metformin (Glucophage)FDA LinkGeneric 12/2020
1	Glucose (Dextrose)FDA LinkGeneric 12/2020

Therapy/Procedure

13	Cardiac Rehabilitation 01/2021 - 03/2008
9	Therapeutics 05/2018 - 07/2002
8	Drug Therapy (Chemotherapy) 01/2019 - 01/2004
4	Transcranial Direct Current Stimulation 01/2022 - 10/2017
4	Institutionalization (Institutionalized Persons) 09/2019 - 11/2010
3	Long-Term Care 12/2020 - 05/2011
3	Transcatheter Aortic Valve Replacement 01/2019 - 01/2015
3	Activities of Daily Living (ADL) 01/2019 - 04/2015
1	Contraindications 01/2022
1	Resistance Training 01/2021
1	Glycemic Control 12/2020
1	Electrodes (Electrode) 09/2020